Prof. Jianming Xu 徐建明
Chief Physician, Professor
Department of Medical Oncology, Chinese PLA General Hospital (301 Hospital), First Medical Center, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of digestive system tumors, including gastric, colorectal, esophageal, liver, pancreatic cancers, gastrointestinal stromal tumors, and neuroendocrine tumors.
Dr. Xu is Director of Digestive Oncology at Chinese PLA General Hospital. Formerly a consultant physician at the National Cancer Institute in Italy for two years. Focuses on medical treatment and research of digestive tumors, particularly molecular targeted therapy. Serves on expert groups for NCCN guidelines and Ministry of Health standards. Published extensively in domestic and international journals.
Professional roles
- Chair, Gastrointestinal Pancreatic Neuroendocrine Cancer Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Tumor Molecular Targeted Drug Therapy Committee, Chinese Association of Biomedical Engineering
- Standing Committee Member, China Geriatric Oncology Committee
- Executive Committee Member, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Xu Jianming). Papers usually list the name as Jianming Xu or Xu J.
Selected publications
78 papers on PubMed matched by name and affiliation; 41 as first or senior author since 2016. Most recent first- or senior-author papers:
- Nat Commun, 2026 (senior author): First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306). PubMed 42834033
- Chin Med J (Engl), 2026 (senior author): Anti-PD-1 monoclonal antibody suppresses hepatitis B virus in patients with hepatocellular carcinoma. PubMed 42260766
- Mol Cancer Ther, 2026 (senior author): Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity. PubMed 41208285
- Ther Adv Med Oncol, 2026 (senior author): Comparative effectiveness of first-line taxane-platinum versus fluorouracil-platinum chemotherapy in advanced esophageal squamous cell carcinoma: a propensity score-matched real-world study. PubMed 42052131
- Discov Oncol, 2026 (senior author): Integrated single-cell and functional analyses define strategies to enhance dendritic cell immunostimulatory capacity. PubMed 41824152
- Cancer Biol Med, 2026 (senior author): Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors. PubMed 41787723
- Cancer Biol Med, 2026 (senior author): First-line immunotherapy for advanced HER2-negative gastric cancer: differences between Asian and non-Asian patients. PubMed 41766111
- Cancer Commun (Lond), 2025 (senior author): Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01). PubMed 41273757
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion